A combination of RAF dimer inhibitor lifirafenib with MEK inhibitor mirdametinib showed antitumor activity in pre-treated several solid tumor types harboring BRAF mutations, including one patient with BRAF V600E NSCLC [46]. The gene discussed is RAF1; the disease is non-small cell lung carcinoma.